Shenzhen Weiguang Biological Products Co Ltd (002880) - Total Assets

Latest as of March 2026: CN¥3.67 Billion CNY ≈ $536.64 Million USD

Based on the latest financial reports, Shenzhen Weiguang Biological Products Co Ltd (002880) holds total assets worth CN¥3.67 Billion CNY (≈ $536.64 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore 002880 operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.

Shenzhen Weiguang Biological Products Co Ltd - Total Assets Trend (2012–2025)

This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002880 book value for net asset value and shareholders' equity analysis.

Shenzhen Weiguang Biological Products Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2025)

Shenzhen Weiguang Biological Products Co Ltd's total assets of CN¥3.67 Billion consist of 45.1% current assets and 54.9% non-current assets.

Asset Category	Amount (CNY)	% of Total Assets
Cash & Equivalents	CN¥0.00	9.9%
Accounts Receivable	CN¥303.38 Million	8.1%
Inventory	CN¥882.73 Million	23.6%
Property, Plant & Equipment	CN¥0.00	0.0%
Intangible Assets	CN¥191.61 Million	5.1%
Goodwill	CN¥19.23 Million	0.5%

Asset Composition Trend (2012–2025)

This chart illustrates how Shenzhen Weiguang Biological Products Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 002880 company net worth.

Show as percentage

Key Asset Composition Facts

Current vs. Non-Current Assets: Shenzhen Weiguang Biological Products Co Ltd's current assets represent 45.1% of total assets in 2025, a decrease from 45.2% in 2012.
Cash Position: Cash and equivalents constituted 9.9% of total assets in 2025, down from 21.0% in 2012.
Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 11.0% in 2012.
Asset Diversification: The largest asset category is inventory at 23.6% of total assets.

Shenzhen Weiguang Biological Products Co Ltd Competitors by Total Assets

Key competitors of Shenzhen Weiguang Biological Products Co Ltd based on total assets are shown below.

Company	Country	Total Assets
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	China	CN¥8.59 Billion
Tubize-Fin BR:TUB	Belgium	€1.93 Billion
Sk Biopharmaceuticals Co Ltd KO:326030	Korea	₩1.20 Trillion
Tango Therapeutics Inc NASDAQ:TNGX	USA	$398.69 Million
TELIX Pharmaceuticals Ltd AU:TLX	Australia	AU$1.19 Billion
Xiamen Amoytop Biotech Co Ltd SHG:688278	China	CN¥3.21 Billion
Hangzhou Biotest Biotech Co Ltd SHG:688767	China	CN¥2.49 Billion
Theravance Biopharma Inc F:0TB	Germany	€415.46 Million

Shenzhen Weiguang Biological Products Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric	Current	1 Year Ago	5 Years Ago
Current Ratio	2.36	3.72	8.28
Quick Ratio	0.83	1.64	4.30
Cash Ratio	0.00	0.00	0.00
Working Capital	CN¥846.53 Million	CN¥1.12 Billion	CN¥851.69 Million

Shenzhen Weiguang Biological Products Co Ltd - Advanced Valuation Insights

This section examines the relationship between Shenzhen Weiguang Biological Products Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio	2.11
Latest Market Cap to Assets Ratio	0.18
Asset Growth Rate (YoY)	13.4%
Total Assets	CN¥3.74 Billion
Market Capitalization	$672.72 Million USD

Valuation Analysis

Below Book Valuation: The market values Shenzhen Weiguang Biological Products Co Ltd's assets below their book value (0.18x), which may indicate investor concerns about asset quality or future growth.

Rapid Asset Growth: Shenzhen Weiguang Biological Products Co Ltd's assets grew by 13.4% over the past year, indicating significant expansion of the company's resource base.

Annual Total Assets for Shenzhen Weiguang Biological Products Co Ltd (2012–2025)

The table below shows the annual total assets of Shenzhen Weiguang Biological Products Co Ltd from 2012 to 2025.

Year	Total Assets	Change
2025-12-31	CN¥3.74 Billion ≈ $547.29 Million	+13.42%
2024-12-31	CN¥3.30 Billion ≈ $482.52 Million	+14.62%
2023-12-31	CN¥2.88 Billion ≈ $420.96 Million	+11.69%
2022-12-31	CN¥2.58 Billion ≈ $376.91 Million	+28.56%
2021-12-31	CN¥2.00 Billion ≈ $293.18 Million	+9.11%
2020-12-31	CN¥1.84 Billion ≈ $268.69 Million	+15.82%
2019-12-31	CN¥1.59 Billion ≈ $231.99 Million	+8.64%
2018-12-31	CN¥1.46 Billion ≈ $213.54 Million	+6.16%
2017-12-31	CN¥1.37 Billion ≈ $201.16 Million	+51.08%
2016-12-31	CN¥909.88 Million ≈ $133.14 Million	+6.30%
2015-12-31	CN¥855.97 Million ≈ $125.25 Million	+11.22%
2014-12-31	CN¥769.59 Million ≈ $112.62 Million	+7.97%
2013-12-31	CN¥712.79 Million ≈ $104.30 Million	+7.08%
2012-12-31	CN¥665.63 Million ≈ $97.40 Million	--

About Shenzhen Weiguang Biological Products Co Ltd

SHE:002880 China Biotechnology

Market Cap

$672.72 Million

CN¥4.60 Billion CNY

Market Cap Rank

#10671 Global

#2866 in China

Share Price

CN¥20.27

Change (1 day)

+0.45%

52-Week Range

CN¥18.80 - CN¥31.04

All Time High

CN¥963796.17